Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
STEMCELL Technologies LY2228820 (Dimesylate), Size: 5 mg
Supplier: STEMCELL Technologies 74164
LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC₅₀ = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.). This product is supplied as the dimesylate salt of the molecule.MAINTENANCE AND SELF-RENEWAL· Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.).CANCER RESEARCH· By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.).
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction